Evidence map›Paper›PMID 28780577›Full record

SynthesisHeart (British Cardiac Society)2018

Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis.

Sean Lee Zheng, Fiona T Chan, Adam A Nabeebaccus, Ajay M Shah, Theresa McDonagh, Darlington O Okonko, Salma Ayis

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Heart (British Cardiac Society), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 8 pooled it
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 8 syntheses or guidelines pooled it, 147 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).Hypertension research : official journal of the Japanese Society of Hypertension · 2019
    Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Sean Lee ZhengCardiovascular Division, King's College Hospital London, British Heart Foundation Centre of Research Excellence, London, UK.
Fiona T ChanImperial College Healthcare NHS Trust, London, UK.
Adam A NabeebaccusCardiovascular Division, King's College Hospital London, British Heart Foundation Centre of Research Excellence, London, UK.
Ajay M ShahCardiovascular Division, King's College Hospital London, British Heart Foundation Centre of Research Excellence, London, UK.
Theresa McDonaghCardiovascular Division, King's College Hospital London, British Heart Foundation Centre of Research Excellence, London, UK.
Darlington O OkonkoCardiovascular Division, King's College Hospital London, British Heart Foundation Centre of Research Excellence, London, UK.
Salma AyisDepartment of Primary Care and Public Health Sciences, King's College London, London, UK.
British Heart Foundation · GBKing's College Hospital · GBImperial College Healthcare NHS Trust · GBKing's College London · GB

Funding

British Heart Foundation FS/14/77/30913British Heart Foundation RG/13/11/30384
6 · The paper itself

Abstract

backgroundClinical drug trials in patients with heart failure and preserved ejection fraction have failed to demonstrate improvements in mortality.

methodsWe systematically searched Medline, Embase and the Cochrane Central Register of Controlled Trials for randomised controlled trials (RCT) assessing pharmacological treatments in patients with heart failure with left ventricular (LV) ejection fraction≥40% from January 1996 to May 2016. The primary efficacy outcome was all-cause mortality. Secondary outcomes were cardiovascular mortality, heart failure hospitalisation, exercise capacity (6-min walk distance, exercise duration, VO

resultsWe included data from 25 RCTs comprising data for 18101 patients. All-cause mortality was reduced with beta-blocker therapy compared with placebo (RR: 0.78, 95%CI 0.65 to 0.94, p=0.008). There was no effect seen with ACE inhibitors, aldosterone receptor blockers, mineralocorticoid receptor antagonists and other drug classes, compared with placebo. Similar results were observed for cardiovascular mortality. No single drug class reduced heart failure hospitalisation compared with placebo.

conclusionThe efficacy of treatments in patients with heart failure and an LV ejection fraction≥40% differ depending on the type of therapy, with beta-blockers demonstrating reductions in all-cause and cardiovascular mortality. Further trials are warranted to confirm treatment effects of beta-blockers in this patient group.

Indexed as

BiomarkersCardiovascular AgentsDisease ProgressionHeart FailureHeart VentriclesHumansRecovery of FunctionRisk FactorsStroke VolumeTreatment OutcomeVentricular Function, LeftBiomarkersCardiovascular Agentsdiastolic dysfunctionheart failuremeta-analysismid-range ejection fractionpreserved ejection fractionsystematic review

Identifiers

PMID28780577
PMCPMC5861385
OpenAlexW2744908275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.